Genital warts and infection with human immunodeficiency virus in high-risk women in Burkina Faso: a longitudinal study
Genital warts and infection with human immunodeficiency virus in high-risk women in Burkina Faso: a longitudinal study
复制标题
DOI：
10.1186/1471-2334-11-20
复制
发表时间：
2011-01-20
影响因子：
3.7
通讯作者：
Mayaud, Philippe
中科院分区：
文献类型：
--
作者：
Low, Andrea J.;Clayton, Tim;Mayaud, Philippe
背景：人乳头瘤病毒是最常见的性传播感染，而由 HPV-6 和 11 引起的生殖器疣会带来相当大的发病率和费用。尚未在非洲女性中描述与 HIV-1 感染相关的尖锐湿疣的自然史。我们在布基纳法索的一组高危女性中检查了尖锐湿疣的危险因素，以进一步描述其流行病学。方法：对布基纳法索的 765 名高危女性进行了一项前瞻性研究，她们每 4 个月进行一次随访，为期 27 个月。 Logistic 和 Cox 回归用于确定与流行、偶发和持续性尖锐湿疣相关的因素，包括 HIV-1 血清状态、CD4+ 计数和并发性传播感染。在 306 名女性的子集中，在入组时对宫颈 HPV DNA 进行了检测。结果：基线时，未感染 HIV 的女性生殖器疣患病率为 1.6% (8/492)，HIV-1 血清阳性女性的基线患病率为 7.0% (19/273)。 40 名女性 (5.2%) 至少经历过一次 GW 发作。在未感染 HIV 的女性中，发病率为每 100 人年 1.1 例；在最低 CD4+ 计数 >200 个细胞/μL 的 HIV-1 血清阳性女性中，发病率为每 100 人年 7.4 例；在 CD4+ 计数最低值的 HIV-1 血清阳性女性中，发病率为每 100 人年 14.6 例
Background: Human papillomaviruses are the most common sexually transmitted infections, and genital warts, caused by HPV-6 and 11, entail considerable morbidity and cost. The natural history of genital warts in relation to HIV-1 infection has not been described in African women. We examined risk factors for genital warts in a cohort of high-risk women in Burkina Faso, in order to further describe their epidemiology.Methods: A prospective study of 765 high-risk women who were followed at 4-monthly intervals for 27 months in Burkina Faso. Logistic and Cox regression were used to identify factors associated with prevalent, incident and persistent genital warts, including HIV-1 serostatus, CD4+ count, and concurrent sexually transmitted infections. In a subset of 306 women, cervical HPV DNA was tested at enrolment.Results: Genital wart prevalence at baseline was 1.6% (8/492) among HIV-uninfected and 7.0% (19/273) among HIV-1 seropositive women. Forty women (5.2%) experienced at least one incident GW episode. Incidence was 1.1 per 100 person-years among HIV-uninfected women, 7.4 per 100 person-years among HIV-1 seropositive women with a nadir CD4+ count >200 cells/mu L and 14.6 per 100 person-years among HIV-1 seropositive women with a nadir CD4+ count